The combination therapy attenuates IMQ-induced psoriasis-like inflammation by downregulating the levels of IL-17A, IL-22, IL-23, and TNF-α in the serum and skin and upregulating Treg cells compared with Acar alone or low-dose CsA alone. This evidence concerns the gene TNF and psoriasis.